Cargando…
Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis
Despite best available therapy, cerebral aspergillosis is an often-lethal complication of disseminated aspergillosis. There is an urgent need to expand the currently limited therapeutic options. In this study, we assessed cerebral drug exposure and efficacy of caspofungin (CAS) using a lethal infant...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241807/ https://www.ncbi.nlm.nih.gov/pubmed/35435756 http://dx.doi.org/10.1128/spectrum.02753-21 |
_version_ | 1784737899434999808 |
---|---|
author | Ullmann, Irina Aregger, Andrea Leib, Stephen L. Zimmerli, Stefan |
author_facet | Ullmann, Irina Aregger, Andrea Leib, Stephen L. Zimmerli, Stefan |
author_sort | Ullmann, Irina |
collection | PubMed |
description | Despite best available therapy, cerebral aspergillosis is an often-lethal complication of disseminated aspergillosis. There is an urgent need to expand the currently limited therapeutic options. In this study, we assessed cerebral drug exposure and efficacy of caspofungin (CAS) using a lethal infant rat model of cerebral aspergillosis. Eleven-day-old Wistar rats were infected by intracisternal injection of Aspergillus fumigatus conidia. Treatment started after 22 h and was continued for 10 days. Regimens were CAS 1 mg/kg/day intraperitoneally (i.p.), liposomal amphotericin B (L-AmB) 5 mg/kg/day i.p., and both drugs combined at the same dose i.p. Infected controls were given NaCl 0.85% i.p. Primary endpoints assessed were survival, cerebral fungal burden, galactomannan index, and drug concentrations in brain homogenate at 2, 3, 5, and 11 days after infection. Compared to those of controls (4.4 ± 2.7 days), survival times were increased by treatment with CAS alone (10.3 ± 1.7 days; P < 0.0001) and CAS combined with L-AmB (9.3 ± 2.8 days; P < 0.0001). In contrast, survival time of L-AmB-treated animals (4.3 ± 3.1 days) was not different from that of controls. Cerebral fungal burden and galactomannan index declined in all animals over time, without significant differences between controls and treated animals. CAS trough levels in brain tissue were between 0.84 and 1.4 μg/g, concentrations we show to be associated with efficacy. AmB trough levels in brain tissue were higher than the MIC of the A. fumigatus isolate. In summary, CAS concentrations in brain tissue suggest it may be therapeutically relevant and it significantly improved survival in this lethal model of cerebral aspergillosis in nonneutropenic rats. The clinical efficacy of CAS treatment for cerebral aspergillosis merits further study. IMPORTANCE Treatment options for cerebral aspergillosis, an often-lethal disease, are limited. The echinocandins (caspofungin is one of them) are not recommended treatment because their brain tissue penetration is often considered insufficient. In a nursing rat model of cerebral aspergillosis that mimics human disease, we found potentially therapeutically relevant concentrations of caspofungin in brain tissue and prolonged survival of caspofungin-treated animals. The efficacy of caspofungin in the treatment of cerebral aspergillosis documented here, if confirmed in other animal models (especially immunosuppressed murine models) and by using additional Aspergillus isolates across a range of CAS minimal effective concentrations (MECs), would suggest that caspofungin merits further study as a treatment option for patients suffering from aspergillosis disseminated to the brain. |
format | Online Article Text |
id | pubmed-9241807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92418072022-06-30 Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis Ullmann, Irina Aregger, Andrea Leib, Stephen L. Zimmerli, Stefan Microbiol Spectr Research Article Despite best available therapy, cerebral aspergillosis is an often-lethal complication of disseminated aspergillosis. There is an urgent need to expand the currently limited therapeutic options. In this study, we assessed cerebral drug exposure and efficacy of caspofungin (CAS) using a lethal infant rat model of cerebral aspergillosis. Eleven-day-old Wistar rats were infected by intracisternal injection of Aspergillus fumigatus conidia. Treatment started after 22 h and was continued for 10 days. Regimens were CAS 1 mg/kg/day intraperitoneally (i.p.), liposomal amphotericin B (L-AmB) 5 mg/kg/day i.p., and both drugs combined at the same dose i.p. Infected controls were given NaCl 0.85% i.p. Primary endpoints assessed were survival, cerebral fungal burden, galactomannan index, and drug concentrations in brain homogenate at 2, 3, 5, and 11 days after infection. Compared to those of controls (4.4 ± 2.7 days), survival times were increased by treatment with CAS alone (10.3 ± 1.7 days; P < 0.0001) and CAS combined with L-AmB (9.3 ± 2.8 days; P < 0.0001). In contrast, survival time of L-AmB-treated animals (4.3 ± 3.1 days) was not different from that of controls. Cerebral fungal burden and galactomannan index declined in all animals over time, without significant differences between controls and treated animals. CAS trough levels in brain tissue were between 0.84 and 1.4 μg/g, concentrations we show to be associated with efficacy. AmB trough levels in brain tissue were higher than the MIC of the A. fumigatus isolate. In summary, CAS concentrations in brain tissue suggest it may be therapeutically relevant and it significantly improved survival in this lethal model of cerebral aspergillosis in nonneutropenic rats. The clinical efficacy of CAS treatment for cerebral aspergillosis merits further study. IMPORTANCE Treatment options for cerebral aspergillosis, an often-lethal disease, are limited. The echinocandins (caspofungin is one of them) are not recommended treatment because their brain tissue penetration is often considered insufficient. In a nursing rat model of cerebral aspergillosis that mimics human disease, we found potentially therapeutically relevant concentrations of caspofungin in brain tissue and prolonged survival of caspofungin-treated animals. The efficacy of caspofungin in the treatment of cerebral aspergillosis documented here, if confirmed in other animal models (especially immunosuppressed murine models) and by using additional Aspergillus isolates across a range of CAS minimal effective concentrations (MECs), would suggest that caspofungin merits further study as a treatment option for patients suffering from aspergillosis disseminated to the brain. American Society for Microbiology 2022-04-18 /pmc/articles/PMC9241807/ /pubmed/35435756 http://dx.doi.org/10.1128/spectrum.02753-21 Text en Copyright © 2022 Ullmann et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Ullmann, Irina Aregger, Andrea Leib, Stephen L. Zimmerli, Stefan Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title | Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title_full | Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title_fullStr | Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title_full_unstemmed | Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title_short | Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis |
title_sort | caspofungin cerebral penetration and therapeutic efficacy in experimental cerebral aspergillosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241807/ https://www.ncbi.nlm.nih.gov/pubmed/35435756 http://dx.doi.org/10.1128/spectrum.02753-21 |
work_keys_str_mv | AT ullmannirina caspofungincerebralpenetrationandtherapeuticefficacyinexperimentalcerebralaspergillosis AT areggerandrea caspofungincerebralpenetrationandtherapeuticefficacyinexperimentalcerebralaspergillosis AT leibstephenl caspofungincerebralpenetrationandtherapeuticefficacyinexperimentalcerebralaspergillosis AT zimmerlistefan caspofungincerebralpenetrationandtherapeuticefficacyinexperimentalcerebralaspergillosis |